China Digest: Zelgen sets IPO terms; TAOS Data nabs $10m

China Digest: Zelgen sets IPO terms; TAOS Data nabs $10m

TAOS Data Team. Source: Visuals from the company website

Chinese pre-profit oncology drugs developer Zelgen has fixed the terms for its IPO on the Shanghai Stock Exchange targeting to raise 2.026 billion yuan ($294 million) while global venture capital firm GGV Capital has led a nearly $10 million Series pre-A round of financing in TAOS Data.

Zelgen Biopharma sets IPO price

Suzhou Zelgen Biopharmaceuticals (Zelgen), an oncology drug developer, has fixed the share price for an initial public offering on the Shanghai Stock Exchange Star Market.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter